Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi ™, which provides improved treatment for patients living with ADA-SCID, better known as “Bubble Boy Disease.” The journey that lead to Revcovi is a prime example of Leadiant’s steadfast dedication to their patients and their rare disease portfolio.
Gaithersburg, MD – October 5, 2018 – Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Leadiant Biosciences, Inc. today announced it has entered into a license agreement and cooperative research and development agreement (CRADA) with the National Institutes of Health (NIH) to develop oral N-acetyl-D-mannosamine (ManNAc) for the potential treatment of individuals with GNE myopathy. GNE myopathy is a rare genetic disorder that causes progressive skeletal muscle atrophy, with an onset in young adulthood, leading to severe disability.
Gaithersburg, MD, (February 28, 2017) – Sigma-Tau Pharmaceuticals, Inc., a leader in the development and commercialization of medicines for patients with rare diseases, today announced that the company has changed its name to Leadiant Biosciences, Inc. reaffirming the company’s continued strong commitment to the patient communities it serves.
